Lab21 to Support New US Cancer Institute With Molecular Diagnostic and Clinical Trial Services
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Lab21 Limited, the Cambridge, UK-based specialist in personalized medicine announces an agreement with the newly-launched Institute for Translational Oncology Research (ITOR) in Greenville, South Carolina to provide molecular diagnostic support services for new initiatives in drug development and advanced cancer patient care.
The new Institute, a part of Greenville Hospital System University Medical Center (GHS) is moving into the arena of personalized gene-targeted cancer therapies and focusing on bringing translational research from the lab to practical application in patients.
Lab21, a provider of personalized medicine services in Europe, recently launched its first venture in North America situating a new clinical reference laboratory and US Headquarters in Greenville.
Lab21 focuses on the global provision of molecular testing services particularly in the oncology and antiviral areas for both patient management and clinical trials. In addition, it has a diagnostics products business and is building a pipeline of proprietary pharmacogenetic and biomarker products which it plans to launch globally from 2011 onwards.
Dr Berwyn Clarke, CSO at Lab21 commented: ‘The close relationship with ITOR will be an enormous asset for Lab21. Not only will it allow us to provide support for ITOR clinical studies but it will give us first-hand daily interaction with cancer physicians which will stimulate early identification and development of new biomarker panels.’
Graham Mullis, Lab21 CEO added ‘The potential relationship with ITOR and GHS was one of the leading reasons why we decide to site our US operation within South Carolina. We have been hugely impressed by the skills and dedication of the ITOR team but, equally importantly, we were delighted that we both a shared vision on the future of stratified medicine and could all see the benefits of our relationship towards the optimised treatment of cancer patients and introduction of diagnostic tools.’
Dr Joe Stephenson, ITOR Medical Director, commented ‘Having Lab21 situated on our doorstep is a significant advantage for ITOR giving us immediate access to a growing portfolio of diagnostic services. Also, the shared vision of the partners will allow us to significantly influence the types of diagnostic panels that Lab21 introduces and develops, enabling us to provide the highest standards of care for our cancer patients.’
The new Institute, a part of Greenville Hospital System University Medical Center (GHS) is moving into the arena of personalized gene-targeted cancer therapies and focusing on bringing translational research from the lab to practical application in patients.
Lab21, a provider of personalized medicine services in Europe, recently launched its first venture in North America situating a new clinical reference laboratory and US Headquarters in Greenville.
Lab21 focuses on the global provision of molecular testing services particularly in the oncology and antiviral areas for both patient management and clinical trials. In addition, it has a diagnostics products business and is building a pipeline of proprietary pharmacogenetic and biomarker products which it plans to launch globally from 2011 onwards.
Dr Berwyn Clarke, CSO at Lab21 commented: ‘The close relationship with ITOR will be an enormous asset for Lab21. Not only will it allow us to provide support for ITOR clinical studies but it will give us first-hand daily interaction with cancer physicians which will stimulate early identification and development of new biomarker panels.’
Graham Mullis, Lab21 CEO added ‘The potential relationship with ITOR and GHS was one of the leading reasons why we decide to site our US operation within South Carolina. We have been hugely impressed by the skills and dedication of the ITOR team but, equally importantly, we were delighted that we both a shared vision on the future of stratified medicine and could all see the benefits of our relationship towards the optimised treatment of cancer patients and introduction of diagnostic tools.’
Dr Joe Stephenson, ITOR Medical Director, commented ‘Having Lab21 situated on our doorstep is a significant advantage for ITOR giving us immediate access to a growing portfolio of diagnostic services. Also, the shared vision of the partners will allow us to significantly influence the types of diagnostic panels that Lab21 introduces and develops, enabling us to provide the highest standards of care for our cancer patients.’
